Decentralized clinical trial company Curebase is partnering with Meru Health on a 3-year clinical trial to study the effectiveness of Meru’s 12-week treatment program for reducing depression in primary care patients.
Meru Health’s smartphone-based, physician-directed treatment program targets depression, burnout, and anxiety, while Curebase provides a decentralized clinical trial platform that connects clinicians study with trial participants, simplifying paperwork and enabling remote study management.
The two-phase trial will begin with a proof-of-concept phase, in which 15 patients will use Meru Health’s treatment program. Another 15 will undergo traditional treatments, such as face-to-face therapy, antidepressants or combination therapy, under the supervision of their primary care physician.
Once the proof-of-concept phase ends, the two companies will team up for a randomized controlled trial (RCT), involving 300 participants and eight primary care clinics in the United States.
During the RCT, Curebase and Meru Health will collect the patient’s electronically reported results for analysis. After the participants completed the treatment program, the researchers tracked their progress for up to one year to assess the sustained impact of the Meru treatment program compared with the standard treatments. standard.
Trials sponsored by National Institutes of Health The Small Business Innovation Research Program and is expected to begin recruiting in the fall of 2022. It is expected to close in the spring of 2023.
Kristian Ranta, founder and CEO of Meru Health, said: “Too many people struggling with mental health issues also struggle with access to effective treatment and solutions. Our legislation was created to help these people.” “Curebase is an ideal partner for us because the company’s DCT platform and support services allow us to focus on the clinical aspects of these trials, while also treating participating patients. at various locations.”
TREND TO BIGGER WOMAN
Several digital health companies provide technology to conduct decentralized clinical trials, including Can be treated, Improve health and TOPIC. Curebase recently closed a $40 million Series B funding round, bringing the total raised to $59 million.
Digital mental health continues to be a popular clinical area to invest in, even in general digital health sponsorship has decreased so far in 2022. Meru raised $38 million in Series B equity and debt capital last year, after a $8.1 million Series A in 2020.
“Meru Health’s smartphone-based mental health program shows great potential in bringing effective and accessible treatment to the growing population of patients with depression and anxiety,” Curebase CEO and founder Tom Lemberg said in a statement. “We’re excited to be partnering with Meru Health on clinical research that has the potential to benefit millions of Americans.”